Author(s):
Manohar D. Kengar, Ganesh B. Vambhurkar Asha M. Jagtap, Akshata S. Gavade, Manojkumar M. Nitalikar
Email(s):
manojkengar200@gmail.com
DOI:
10.5958/2231-5659.2018.00043.7 
Address:
Manohar D. Kengar*, Ganesh B. Vambhurkar Asha M. Jagtap, Akshata S. Gavade, Manojkumar M. Nitalikar
Rajarambapu College of Pharmacy, Kasegaon, Dist–Sangli, Maharashtra, India–415404.
*Corresponding Author
Published In:
Volume - 8,
Issue - 4,
Year - 2018
ABSTRACT:
The numbers of single drugs as well as fixed dose combinations drugs are banned in other countries but they have manufacturing, marketing and distribution in India. Over the counter availability of banned drugs sufficient adverse drug reactions data about these drugs have not been reported. The adverse effect of drugs is detected by regular monitoring after the drug released called pharmacovigilance. The Indian regulatory authority monitoring the new drug in market before pre-clinical study and permit to sold in market. The banned dugs prescribed over the counter the responsible as unawareness of physicians and patients, poverty, self-medication, carelessness of regulatory authorities, non availability of appropriate drugs, high cost, and communication. The Government of India is in the process of developing a regulatory regime designed to ensure the quality, safety and performance of medical devices.
Cite this article:
Manohar D. Kengar, Ganesh B. Vambhurkar Asha M. Jagtap, Akshata S. Gavade, Manojkumar M. Nitalikar. A Study on Banned Drugs in India: A Review. Asian J. Res. Pharm. Sci. 2018; 8(4): 258-260. doi: 10.5958/2231-5659.2018.00043.7
Cite(Electronic):
Manohar D. Kengar, Ganesh B. Vambhurkar Asha M. Jagtap, Akshata S. Gavade, Manojkumar M. Nitalikar. A Study on Banned Drugs in India: A Review. Asian J. Res. Pharm. Sci. 2018; 8(4): 258-260. doi: 10.5958/2231-5659.2018.00043.7 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2018-8-4-13